41052-88-4

Basic information

• Product Name: CHEMBRDG-BB 6474172
• Synonyms: CHEMBRDG-BB 6474172;3-ALLYL-4-HYDROXYBENZALDEHYDE;3-allyl-4-hydroxybenzaldehyde(SALTDATA: FREE)
• CAS NO: 41052-88-4
• Molecular Formula: C₁₀H₁₀O₂
• Molecular Weight: 162.19
• Mol File: 41052-88-4.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 283.3°C at 760 mmHg
• Flash Point: 118.8°C
• Appearance: /
• Density: 1.126g/cm³
• Vapor Pressure: 0.00186mmHg at 25°C
• Refractive Index: 1.593
• PKA: 8.10±0.18(Predicted)
• CAS DataBase Reference: CHEMBRDG-BB 6474172(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 6474172(41052-88-4)
• EPA Substance Registry System: CHEMBRDG-BB 6474172(41052-88-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 41052-88-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H10O2/c1-2-3-9-6-8(7-11)4-5-10(9)12/h2,4-7,12H,1,3H2

Upstream product

• 101-84-8 diphenylether 
• 40663-68-1 4-(2-propenyloxy)benzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 106-95-6 allyl bromide 
• 28090-12-2 4-(3-methyl-but-2-enyloxy)-benzaldehyde 

Downstream Products

• 67483-48-1 3-allyl-4-methoxybenzaldehyde 
• 136433-45-9 3-allyl-4-allyloxybenzaldehyde 
• 863659-50-1 3-(prop-1-enyl)-4-(prop-1-enyloxy)benzaldehyde 
• 10035-16-2 benzofuran-5-carbaldehyde 
• 638214-85-4 ethyl (2E)-3-[4-hydroxy-3-(2-propen-1-yl)phenyl]-2-propenoate 
• 915920-48-8 3-allyl-4-isopropoxybenzaldehyde 
• 1381841-08-2 C₂₆H₃₃N₇O₄S₂ 
• 1548332-51-9 (1E,4E)-1-(3-allyl-4-methoxyphenyl)-5-[2-(trifluoromethyl)phenyl]penta-1,4-dien-3-one 
• 1577187-47-3 (1E,4E)-1-(3-allyl-4-methoxyphenyl)-5-(5-fluoro-2-methoxyphenyl)penta-1,4-dien-3-one 
• 1548332-59-7 (1E,4E)-1-(3-allyl-4-methoxyphenyl)-5-(2,4,5-trimethoxyphenyl)penta-1,4-dien-3-one 
• 1548331-36-7 (1E,4Ε)-1,5-bis(3-allyl-4-hydroxyphenyl)penta-1,4-dien-3-one 
• 1577187-15-5 (2E,5E)-2,5-bis{3-allyl-4-[(tetrahydro-2H-pyran-2-yl)oxy]benzylidene}cyclopentanone 
• 1548331-45-8 (2E,5E)-2,5-bis(3-allyl-4-hydroxybenzylidene)cyclopentanone 

Relevant articles and documents

Allylphenols as a new class of human 15-lipoxygenase-1 inhibitors

In this study, a series of mono- and diallylphenol derivative were designed, synthesized, and evaluated as potential human 15-lipoxygenase-1 (15-hLOX-1) inhibitors. Radical scavenging potency of the synthetic allylphenol derivatives was assessed and the results were in accordance with lipoxygenase (LOX) inhibition potency. It was found that the electronic natures of allyl moiety and para substituents play the main role in radical scavenging activity and subsequently LOX inhibition potency of the synthetic inhibitors. Among the synthetic compounds, 2,6-diallyl-4-(hexyloxy)phenol (42) and 2,6-diallyl-4-aminophenol (47) showed the best results for LOX inhibition (IC50 = 0.88 and 0.80 μM, respectively).

A Monooxygenase from Boreostereum vibrans Catalyzes Oxidative Decarboxylation in a Divergent Vibralactone Biosynthesis Pathway

The oxidative decarboxylation of prenyl 4-hydroxybenzoate to prenylhydroquinone has been frequently proposed for the biosynthesis of prenylated (hydro)quinone derivates (sometimes meroterpenoids), yet no corresponding genes or enzymes have so far been reported. A FAD-binding monooxygenase (VibMO1) was identified that converts prenyl 4-hydroxybenzoate into prenylhydroquinone and is likely involved in the biosynthesis of vibralactones and other meroterpenoids in the basidiomycete Boreostereum vibrans. Feeding of 3-allyl-4-hydroxybenzylalcohol, an analogue of the vibralactone pathway intermediate 3-prenyl-4-hydroxybenzylalcohol, generated 20 analogues with different scaffolds. This demonstrated divergent pathways to skeletally distinct compounds initiating from a single precursor, thus providing the first insight into a novel biosynthetic pathway for 3-substituted γ-butyrolactones from a shikimate origin.

INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME

Disclosed herein are inhibitors of the Notch transcriptional activation complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: Formula (I), wherein the substituents are as described.